This is an amazing result - 2-3 fold underlying correction in-vitro
additional updates:
- CNS firing up now for patient derived models/animal studies (Thank God we have the infrastructure know-how and experience - hopefully will shave some time)
- 2023 Q1 - phase 1/2 clinical trials commence for our VP-001
- 2024 second lead drug for ADOA to commence clinical trials
If all three made it to market, and additional PYC programs (9 at one point) convert to tangible leads that also partner with tier 1 research foundations what will become of PYC?
Ann: Central Nervous System Drug Program Added to PYC Pipeline, page-3
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $350.7K | 1.962M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 414917 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 236899 | 3 |
View Market Depth
| Last trade - 10.52am 27/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |